Letter: sequential or combined systemic treatment for unresectable hepatocellular carcinoma-authors' reply

被引：0
|
作者：
Kirstein, Martha M. [1 ,2 ]
Scheiner, Bernhard [3 ]
Pinter, Matthias [3 ]
Vogel, Arndt [1 ]
机构：
[1] Hannover Med Sch, Dept Gastroenterol Hepatol & Endocrinol, Hannover, Germany
[2] Univ Med Ctr Schleswig Holstein, Dept Med 1, Lubeck, Germany
[3] Med Univ Vienna, Dept Internal Med 3, Div Gastroenterol & Hepatol, Vienna, Austria
来源：
ALIMENTARY PHARMACOLOGY & THERAPEUTICS | 2020年 / 52卷 / 05期
关键词：
SORAFENIB;
D O I：
10.1111/apt.15980
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
LINKED CONTENT This article is linked to Kirstein et al and Mo et al papers. To view these articles, visit and
引用
收藏
页码：917 / 918
页数：2
相关论文
共 50 条
  • [41] TREATMENT OF UNRESECTABLE HEPATOCELLULAR-CARCINOMA
    VAUTHEY, JN
    MARSH, RD
    DAVIS, GL
    NEW ENGLAND JOURNAL OF MEDICINE, 1995, 333 (13): : 877 - 877
  • [42] Sorafenib for the Treatment of Unresectable Hepatocellular Carcinoma
    Kane, Robert C.
    Farrell, Ann T.
    Madabushi, Rajanikanth
    Booth, Brian
    Chattopadhyay, Somesh
    Sridhara, Rajeshwari
    Justice, Robert
    Pazdur, Richard
    ONCOLOGIST, 2009, 14 (01): : 95 - 100
  • [43] Interventional treatment for unresectable hepatocellular carcinoma
    Murata, Satoru
    Mine, Takahiko
    Sugihara, Fumie
    Yasui, Daisuke
    Yamaguchi, Hidenori
    Ueda, Tatsuo
    Onozawa, Shiro
    Kumita, Shin-ichiro
    WORLD JOURNAL OF GASTROENTEROLOGY, 2014, 20 (37) : 13453 - 13465
  • [44] Sorafenib for the treatment of unresectable hepatocellular carcinoma
    Furuse, Junji
    BIOLOGICS-TARGETS & THERAPY, 2008, 2 (04): : 779 - 788
  • [45] Hepatic arterial infusion therapy for advanced hepatocellular carcinoma after systemic treatment failure: A treatment dilemma-Authors' reply
    Yi, Jun-Zhe
    Lyu, Ning
    Zhao, Ming
    HEPATOLOGY RESEARCH, 2024, 54 (12) : 1236 - 1237
  • [46] Current Role of Atezolizumab Plus Bevacizumab Therapy in the Sequential Treatment of Unresectable Hepatocellular Carcinoma
    Komatsu, Shohei
    Yano, Yoshihiko
    Fujishima, Yoshimi
    Ishida, Jun
    Kido, Masahiro
    Kuramitsu, Kaori
    Yamamoto, Atsushi
    Goto, Tadahiro
    Yanagimoto, Hiroaki
    Toyama, Hirochika
    Ueda, Yoshihide
    Kodama, Yuzo
    Fukumoto, Takumi
    ANTICANCER RESEARCH, 2022, 42 (03) : 1403 - 1412
  • [47] EBM and the diagnosis of hepatocellular carcinoma - Authors' reply
    Burroughs, AK
    Fung, KTT
    Li, FTW
    Raimondo, ML
    Maudgil, D
    Mancuso, A
    Tibballs, JM
    Watkinson, AA
    Patch, A
    BRITISH JOURNAL OF RADIOLOGY, 2005, 78 (928): : 371 - 372
  • [48] Letter: hepatocellular carcinoma risk after hepatitis B surface antigen seroclearance - authors' reply
    Gounder, P. P.
    Mosites, E. M.
    McMahon, B. J.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2017, 45 (09) : 1288 - 1289
  • [49] Letter: is tenofovir superior to entecavir for hepatocellular carcinoma prevention in chronic hepatitis B? Authors' reply
    Yip, Terry C. -F.
    Wong, Grace L. -H.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2020, 51 (02) : 315 - 316
  • [50] Letter: hepatitis B surface seroclearance does reduce the risk of hepatocellular carcinoma - authors' reply
    Gounder, P. P.
    Bulkow, L. R.
    McMahon, B. J.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2016, 44 (06) : 650 - 651
12345